Jubilant Pharmova gets 8 USFDA obervations for Nanjangud facility
Advertisement
Noida: Jubilant Pharmova Limited has recently announced that the United States Food and Drug Administration (USFDA) has issued eight observations pursuant to the completion of the inspection at the company's API manufacturing facility at Nanjangud, India.
The inspection was concluded on December 13, 2022.
"The company will submit an action plan on the observations and will engage with US FDA for next steps," the company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.